UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D
Notice of Exempt Offering of Securities

1. Issuer's Identity

CIK (Filer ID Number)  Previous Names  Entity Type
0000863894  None  X Corporation

Name of Issuer
FEMALE HEALTH CO
Jurisdiction of Incorporation/Organization
WISCONSIN
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
FEMALE HEALTH CO
Street Address 1  Street Address 2
150 NORTH MICHIGAN AVENUE  STE 1580
City  State/Province/Country  ZIP/PostalCode  Phone Number of Issuer
CHICAGO  ILLINOIS  60601  3125959123

3. Related Persons

Last Name  First Name  Middle Name  Relationship
Steiner  Mitchell  S.  X Executive Officer  X Director  Promoter

Clarification of Response (if Necessary):
President and Chief Executive Officer

Last Name  First Name  Middle Name  Relationship
Haines  Daniel
Street Address 1  Street Address 2
150 North Michigan Avenue  Suite 1580
City  State/Province/Country  ZIP/PostalCode
Chicago  ILLINOIS  60601
X Executive Officer  Director  Promoter
<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peerschke</td>
<td>Elgar</td>
<td></td>
</tr>
<tr>
<td>Street Address 1</td>
<td>Street Address 2</td>
<td></td>
</tr>
<tr>
<td>150 North Michigan Avenue</td>
<td>Suite 1580</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td>State/Province/Country</td>
<td>ZIP/PostalCode</td>
</tr>
<tr>
<td>Chicago</td>
<td>ILLINOIS</td>
<td>60601</td>
</tr>
<tr>
<td>Relationship:</td>
<td>Executive Officer X</td>
<td>Director</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fisch</td>
<td>Harry</td>
<td></td>
</tr>
<tr>
<td>Street Address 1</td>
<td>Street Address 2</td>
<td></td>
</tr>
<tr>
<td>150 North Michigan Avenue</td>
<td>Suite 1580</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td>State/Province/Country</td>
<td>ZIP/PostalCode</td>
</tr>
<tr>
<td>Chicago</td>
<td>ILLINOIS</td>
<td>60601</td>
</tr>
<tr>
<td>Relationship:</td>
<td>Executive Officer X</td>
<td>Director</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Makhoul</td>
<td>Georges</td>
<td></td>
</tr>
<tr>
<td>Street Address 1</td>
<td>Street Address 2</td>
<td></td>
</tr>
<tr>
<td>150 North Michigan Avenue</td>
<td>Suite 1580</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td>State/Province/Country</td>
<td>ZIP/PostalCode</td>
</tr>
<tr>
<td>Chicago</td>
<td>ILLINOIS</td>
<td>60601</td>
</tr>
<tr>
<td>Relationship:</td>
<td>Executive Officer X</td>
<td>Director</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eisenberger</td>
<td>Mario</td>
<td></td>
</tr>
<tr>
<td>Street Address 1</td>
<td>Street Address 2</td>
<td></td>
</tr>
<tr>
<td>150 North Michigan Avenue</td>
<td>Suite 1580</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td>State/Province/Country</td>
<td>ZIP/PostalCode</td>
</tr>
<tr>
<td>Chicago</td>
<td>ILLINOIS</td>
<td>60601</td>
</tr>
<tr>
<td>Relationship:</td>
<td>Executive Officer X</td>
<td>Director</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu</td>
<td>Lucy</td>
<td></td>
</tr>
<tr>
<td>Street Address 1</td>
<td>Street Address 2</td>
<td></td>
</tr>
<tr>
<td>150 North Michigan Avenue</td>
<td>Suite 1580</td>
<td></td>
</tr>
<tr>
<td>City</td>
<td>State/Province/Country</td>
<td>ZIP/PostalCode</td>
</tr>
<tr>
<td>Chicago</td>
<td>ILLINOIS</td>
<td>60601</td>
</tr>
<tr>
<td>Relationship:</td>
<td>Executive Officer X</td>
<td>Director</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parrish</td>
<td>O.B.</td>
<td></td>
</tr>
<tr>
<td>Street Address 1</td>
<td>Street Address 2</td>
<td></td>
</tr>
</tbody>
</table>
Clarification of Response (if Necessary):

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bethune</td>
<td>David</td>
<td>R.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clarification of Response (if Necessary):

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frank</td>
<td>Mary</td>
<td>Margaret</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. Industry Group

- Agriculture
- Banking & Financial Services
  - Commercial Banking
  - Insurance
  - Investing
  - Investment Banking
  - Pooled Investment Fund
- Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No
- Other Banking & Financial Services
- Business Services
- Energy
  - Coal Mining
  - Electric Utilities
  - Energy Conservation
  - Environmental Services
  - Oil & Gas
  - Other Energy
- Health Care
  - Biotechnology
  - Health Insurance
  - Hospitals & Physicians
  - X Pharmaceuticals
  - Other Health Care
  - Manufacturing
  - Real Estate
    - Commercial
    - Construction
    - REITS & Finance
    - Residential
  - Other Real Estate
- Retailing
- Restaurants
- Technology
  - Computers
  - Telecommunications
  - Other Technology
- Travel
  - Airlines & Airports
  - Lodging & Conventions
  - Tourism & Travel Services
  - Other Travel
  - Other

5. Issuer Size

<table>
<thead>
<tr>
<th>Revenue Range</th>
<th>OR</th>
<th>Aggregate Net Asset Value Range</th>
</tr>
</thead>
</table>
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

- Rule 504(b)(1) (not (i), (ii) or (iii))
- Rule 504(b)(1)(i)
- Rule 504(b)(1)(ii)
- Rule 504(b)(1)(iii)
- Rule 505
- X Rule 506(b)
- Rule 506(c)
- Securities Act Section 4(a)(5)
- Investment Company Act Section 3(c)
  - Section 3(c)(1)
  - Section 3(c)(2)
  - Section 3(c)(3)
  - Section 3(c)(4)
  - Section 3(c)(5)
  - Section 3(c)(6)
  - Section 3(c)(7)
  - Section 3(c)(9)
  - Section 3(c)(10)
  - Section 3(c)(11)
  - Section 3(c)(12)
  - Section 3(c)(13)
  - Section 3(c)(14)

7. Type of Filing

- X New Notice  Date of First Sale 2016-10-31  First Sale Yet to Occur
- Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?  Yes  X  No

9. Type(s) of Securities Offered (select all that apply)

- X Equity
- Debt
- Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
- Pooled Investment Fund Interests
- Tenant-in-Common Securities
- Mineral Property Securities
- Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?  X Yes  No

Clarification of Response (if Necessary):

Shares issued in connection with acquisition of Aspen Park Pharmaceuticals, Inc. in merger transaction with Issuer's subsidiary.

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient  Recipient CRD Number  None
Financial West Group  16668
(Associated) Broker or Dealer  None  (Associated) Broker or Dealer CRD Number  None
None  16668
13. Offering and Sales Amounts

Total Offering Amount  $22,676,728 USD  or  Indefinite
Total Amount Sold  $22,676,728 USD
Total Remaining to be Sold  $0 USD  or  Indefinite

Clarification of Response (if Necessary):

Based on closing market price of Issuer’s common stock on 10/31/16.

14. Investors

X  Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

1
23

15. Sales Commissions & Finder’s Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions  $0 USD  Estimate
Finders’ Fees  $973,906 USD  Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD  Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the
Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

<table>
<thead>
<tr>
<th>Issuer</th>
<th>Signature</th>
<th>Name of Signer</th>
<th>Title</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEMALE HEALTH CO</td>
<td>/s/ Daniel Haines</td>
<td>Daniel Haines</td>
<td>CFO, COO and Secretary</td>
<td>2016-11-09</td>
</tr>
</tbody>
</table>

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.